uPA and uPA-receptor are involved in cancer-associated myeloid-derived suppressor cell accumulation

Anticancer Research

Volumn 32, Issue 10, 2012, Pages 4263-4270

  Ilkovitch, Dan ^a   Carrio, Roberto ^b,c   Lopez, Diana M ^b,c  

^a MOUNT SINAI MEDICAL CENTER   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MIAMI   (United States)

Author keywords

Bone marrow; MDSC; Myeloid derived suppressor cells; uPA; uPA receptor

Indexed keywords

CD11B ANTIGEN; UROKINASE; UROKINASE RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW CELL; CELL COMPARTMENTALIZATION; MOUSE; MYELOID DERIVED SUPPRESSOR CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SUPPRESSOR CELL; TUMOR VOLUME;

ANIMALS; ANTIGENS, CD11; CARCINOMA, LEWIS LUNG; FEMALE; GENE KNOCKDOWN TECHNIQUES; MAMMARY NEOPLASMS, ANIMAL; MELANOMA; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MYELOID CELLS; RECEPTORS, UROKINASE PLASMINOGEN ACTIVATOR; T-LYMPHOCYTES, REGULATORY; TUMOR BURDEN; TUMOR CELLS, CULTURED; UROKINASE-TYPE PLASMINOGEN ACTIVATOR;

EID: 84867792293     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (64)

1. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C et al: Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313: 1960-1964, 2006. (Pubitemid 44498003)
2. Turk MJ, Guevara-Patino JA, Rizzuto GA, Engelhorn ME, Sakaguchi S and Houghton AN: Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med 200: 771-782, 2004. (Pubitemid 39299463)
3. North RJ: Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells. J Exp Med 155: 1063-1074, 1982.
4. Fu YX, Watson G, Jimenez JJ, Wang Y and Lopez DM: Expansion of immunoregulatory macrophages by granulocyte-macrophage colony-stimulating factor derived from a murine mammary tumor. Cancer Res 50: 227-234, 1990. (Pubitemid 20041218)
5. Watson GA, Fu YX and Lopez DM: Splenic macrophages from tumor-bearing mice co-expressing MAC-1 and MAC-2 antigens exert immunoregulatory functions via two distinct mechanisms. J Leukoc Biol 49: 126-138, 1991.
6. Serafini P, Borrello I and Bronte V: Myeloid suppressor cells in cancer: recruitment, phenotype, properties, and mechanisms of immune suppression. Semin Cancer Biol 16: 53-65, 2006. (Pubitemid 43139709)
7. Gabrilovich DI and Nagaraj S: Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 9: 162-174, 2009.
8. Bunt SK, Yang L, Sinha P, Clements VK, Leips J and Ostrand-Rosenberg S: Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res. 67: 10019-10026, 2007. (Pubitemid 47621253)
9. Movahedi K, Guilliams M, Van den Bossche J, Van den Bergh R, Gysemans C, Beschin A et al: Identification of discrete tumor-induced myeloid-derived suppressor cell subpopulations with distinct T-cell suppressive activity. Blood. 2008.
10. Rodriguez PC, Hernandez CP, Quiceno D, Dubinett SM, Zabaleta J, Ochoa JB et al: Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma. J Exp Med 202: 931-939, 2005. (Pubitemid 41396893)
11. Bronte V and Zanovello P: Regulation of immune responses by L-arginine metabolism. Nat Rev Immunol 5: 641-654, 2005. (Pubitemid 41113195)
12. Liu C, Yu S, Kappes J, Wang J, Grizzle WE, Zinn KR et al: Expansion of spleen myeloid suppressor cells represses NK cell cytotoxicity in tumor-bearing host. Blood 109: 4336-4342, 2007. (Pubitemid 46743401)
13. Sinha P, Clements VK, Bunt SK, Albelda SM and Ostrand-Rosenberg S: Cross-talk between myeloid-derived suppressor cells and macrophages subverts tumor immunity toward a type 2 response. J Immunol 179: 977-983, 2007.
14. Ilkovitch D and Lopez DM: The liver is a site for tumor-induced myeloid-derived suppressor cell accumulation and immunosuppression. Cancer Res 69: 5514-5521, 2009.
15. Grondahl-Hansen J, Agerlin N, Munkholm-Larsen P, Bach F, Nielsen LS, Dombernowsky P et al: Sensitive and specific enzyme-linked immunosorbent assay for urokinase-type plasminogen activator and its application to plasma from patients with breast cancer. The Journal of laboratory and clinical medicine 111: 42-51, 1988. (Pubitemid 18082736)
16. Gupta A, Lotan Y, Ashfaq R, Roehrborn CG, Raj GV, Aragaki CC et al: Predictive Value of the Differential Expression of the Urokinase Plasminogen Activation Axis in Radical Prostatectomy Patients. European urology. 2008.
17. Stabuc B, Markovic J, Bartenjev I, Vrhovec I, Medved U and Kocijancic B: Urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 and type 2 in stage I malignant melanoma. Oncology reports 10: 635-639, 2003.
18. Leung KC, Tung Y, Ali M and Lau WN: Measurement of urokinase-type plasminogen activator activity in sera of nasopharyngeal carcinoma patients by an immunocapture assay. Cancer letters 58: 233-240, 1991.
19. Huber K, Kirchheimer JC, Sedlmayer A, Bell C, Ermler D and Binder BR: Clinical value of determination of urokinase-type plasminogen activator antigen in plasma for detection of colorectal cancer: comparison with circulating tumor-associated antigens CA 19-9 and carcinoembryonic antigen. Cancer Res 53: 1788-1793, 1993. (Pubitemid 23127104)
20. Bezerra JA, Currier AR, Melin-Aldana H, Sabla G, Bugge TH, Kombrinck KW et al: Plasminogen activators direct reorganization of the liver lobule after acute injury. Am J Pathol 158: 921-929, 2001. (Pubitemid 32221784)
21. Bryer SC, Fantuzzi G, Van Rooijen N and Koh TJ: Urokinase-type plasminogen activator plays essential roles in macrophage chemotaxis and skeletal muscle regeneration. J Immunol 180: 1179-1188, 2008.
22. Luikart SD, Levay-Young B, Hinkel T, Shearer J, Mills C, Caldwell MD et al: Mactinin treatment promotes wound-healing-associated inflammation in urokinase knockout mice. Wound Repair Regen 14: 123-128, 2006.
23. Sonoda KH, Nakamura T, Young HA, Hart D, Carmeliet P and Stein-Streilein J: NKT cell-derived urokinase-type plasminogen activator promotes peripheral tolerance associated with eye. J Immunol 179: 2215-2222, 2007.
24. Carmeliet P, Collen D: Development and disease in proteinase-deficient mice: role of the plasminogen, matrix metalloproteinase and coagulation system. Thrombosis Res 91: 255-285, 1998. (Pubitemid 28454725)
25. Ilkovitch D and Lopez DM: Urokinase-mediated recruitment of myeloid-derived suppressor cells and their suppressive mechanisms are blocked by MUC1/sec. Blood 113: 4729-4739, 2009.
26. Pluskota E, Soloviev DA and Plow EF: Convergence of the adhesive and fibrinolytic systems: recognition of urokinase by integrin alpha Mbeta 2 as well as by the urokinase receptor regulates cell adhesion and migration. Blood 101: 1582-1590, 2003. (Pubitemid 36182538)
27. Blasi F and Carmeliet P: uPAR: a versatile signalling orchestrator. Nat Rev Mol Cell Biol 3: 932-943, 2002. (Pubitemid 35477371)
28. Crippa MP: Urokinase-type plasminogen activator. The international journal of biochemistry & cell biology 39: 690-694, 2007.
29. Shetty S, Rao GN, Cines DB and Bdeir K: Urokinase induces activation of STAT3 in lung epithelial cells. American J Physiol 291: L772-780, 2006. (Pubitemid 44498490)
30. Stephens RW, Nielsen HJ, Christensen IJ, Thorlacius-Ussing O, Sorensen S, Dano K et al: Plasma urokinase receptor levels in patients with colorectal cancer: relationship to prognosis. J Natl Cancer Inst 91: 869-874, 1999. (Pubitemid 29252303)
31. Ilkovitch D and Lopez DM: Immune modulation by melanoma-derived factors. Experimental dermatology 17: 977-985, 2008.
32. Handel-Fernandez ME, Cheng X, Herbert LM and Lopez DM: Down-regulation of IL-12, not a shift from a T helper-1 to a T helper-2 phenotype, is responsible for impaired IFN-gamma production in mammary tumor-bearing mice. J Immunol 158: 280-286, 1997. (Pubitemid 127483866)
33. Calderon C, Huang ZH, Gage DA, Sotomayor EM and Lopez DM: Isolation of a nitric oxide inhibitor from mammary tumor cells and its characterization as phosphatidyl serine. J Exp Med 180: 945-958, 1994. (Pubitemid 24256607)
34. Owen JL, Iragavarapu-Charyulu V, Gunja-Smith Z, Herbert LM, Grosso JF and Lopez DM: Up-regulation of matrix metalloproteinase-9 in T lymphocytes of mammary tumor bearers: role of vascular endothelial growth factor. J Immunol 171: 4340-4351, 2003. (Pubitemid 37238712)
35. Handel-Fernandez ME, Ilkovitch D, Iragavarapu-Charyulu V, Herbert LM and Lopez DM: Decreased levels of both Stat1 and Stat3 in T lymphocytes from mice bearing mammary tumors. Anticancer Res 29: 2051-2058, 2009.
36. Ilkovitch D, Handel-Fernandez ME, Herbert LM and Lopez DM: Antitumor effects of Mucin 1/sec involves the modulation of urokinase-type plasminogen activator and signal transducer and activator of transcription 1 expression in tumor cells. Cancer Res 68: 2427-2435, 2008. (Pubitemid 351521818)
37. Al-Atrash G, Kitson RP, Xue Y, Mazar AP, Kim MH and Goldfarb RH: uPA and uPAR contribute to NK cell invasion through the extracellular matrix. Anticancer Res 21: 1697-1704, 2001. (Pubitemid 32728902)
38. Zhang J, Sud S, Mizutani K, Gyetko MR and Pienta KJ: Activation of urokinase plasminogen activator and its receptor axis is essential for macrophage infiltration in a prostate cancer mouse model. Neoplasia, New York, NY 13: 23-30, 2011.
39. Bianchi E, Ferrero E, Fazioli F, Mangili F, Wang J, Bender JR et al: Integrin-dependent induction of functional urokinase receptors in primary T lymphocytes. J Clin Investigation 98: 1133-1141, 1996. (Pubitemid 26299926)
40. + cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer cell 6: 409-421, 2004.
41. Melani C, Sangaletti S, Barazzetta FM, Werb Z and Colombo MP: Amino-biphosphonate-mediated MMP-9 inhibition breaks the tumor-bone marrow axis responsible for myeloid-derived suppressor cell expansion and macrophage infiltration in tumor stroma. Cancer Res 67: 11438-11446, 2007. (Pubitemid 350248572)
42. + myeloid cells derived from tumor-bearing mice inhibit primary T cell activation induced through CD3/CD28 costimulation. J Immunol 165: 779-785, 2000.
43. Sinha P, Clements VK and Ostrand-Rosenberg S: Reduction of myeloid-derived suppressor cells and induction of M1 macrophages facilitate the rejection of established metastatic disease. J Immunol 174: 636-645, 2005. (Pubitemid 40094255)
44. + myeloid suppressor cells cause T cell dysfunction after traumatic stress. J Immunol 176: 2085-2094, 2006.
45. Noel JG, Osterburg A, Wang Q, Guo X, Byrum D, Schwemberger S et al: Thermal injury elevates the inflammatory monocyte subpopulation in multiple compartments. Shock Augusta, Ga. 28: 684-693, 2007. (Pubitemid 350135473)
46. Delano MJ, Scumpia PO, Weinstein JS, Coco D, Nagaraj S, Kelly-Scumpia KM et al: MyD88-dependent expansion of an immature GR-1(+)CD11b(+) population induces T cell suppression and Th2 polarization in sepsis. J Exp Med 204: 1463-1474, 2007. (Pubitemid 46919883)
47. Youn JI, Nagaraj S, Collazo M and Gabrilovich DI: Subsets of myeloid-derived suppressor cells in tumor-bearing mice. J Immunol 181: 5791-5802, 2008.
48. Filipazzi P, Valenti R, Huber V, Pilla L, Canese P, Iero M et al: Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine. J Clin Oncol 25: 2546-2553, 2007. (Pubitemid 47041228)
49. Diaz-Montero CM, Salem ML, Nishimura MI, Garrett-Mayer E, Cole DJ and Montero AJ: Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin- cyclophosphamide chemotherapy. Cancer Immunol Immunother 58: 49-59, 2009.
50. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC et al: Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 166: 678-689, 2001. (Pubitemid 32038493)
51. Kusmartsev S, Su Z, Heiser A, Dannull J, Eruslanov E, Kubler H et al: Reversal of myeloid cell-mediated immunosuppression in patients with metastatic renal cell carcinoma. Clin Cancer Res 14: 8270-8278, 2008.
52. Hoechst B, Ormandy LA, Ballmaier M, Lehner F, Kruger C, Manns MP et al: A new population of myeloid-derived suppressor cells in hepatocellular carcinoma patients induces CD4(+)CD25(+) Foxp3(+) T cells. Gastroenterology 135: 234-243, 2008. (Pubitemid 351899008)
53. Serafini P, Mgebroff S, Noonan K and Borrello I: Myeloid-derived suppressor cells promote cross-tolerance in B-cell lymphoma by expanding regulatory T cells. Cancer Res 68: 5439-5449, 2008.
54. + immature myeloid suppressor cells mediate the development of tumor-induced T regulatory cells and T-cell anergy in tumor-bearing host. Cancer Res 66: 1123-1131, 2006.
55. de Paulis A, Montuori N, Prevete N, Fiorentino I, Rossi FW, Visconte V et al: Urokinase induces basophil chemotaxis through a urokinase receptor epitope that is an endogenous ligand for formyl peptide receptor-like 1 and -like 2. J Immunol 173: 5739-5748, 2004. (Pubitemid 39392163)
56. Ferrero E, Vettoretto K, Bondanza A, Villa A, Resnati M, Poggi A et al: uPA/uPAR system is active in immature dendritic cells derived from CD14 +CD34+ precursors and is down-regulated upon maturation. J Immunol 164: 712-718, 2000. (Pubitemid 30043692)
57. Gyetko MR, Chen GH, McDonald RA, Goodman R, Huffnagle GB, Wilkinson CC et al: Urokinase is required for the pulmonary inflammatory response to Cryptococcus neoformans. A murine transgenic model. J Clin Investigation 97: 1818-1826, 1996.
58. Van Den Broeck T, Stevenaert F, Taveirne S, Debacker V, Vangestel C, Vandekerckhove B et al: Ly49E-dependent inhibition of natural killer cells by urokinase plasminogen activator. Blood 112: 5046-5051, 2008.
59. Grondahl-Hansen J, Peters HA, van Putten WL, Look MP, Pappot H, Ronne E et al: Prognostic significance of the receptor for urokinase plasminogen activator in breast cancer. Clin Cancer Res 1: 1079-1087, 1995.
60. Meijer-van Gelder ME, Look MP, Peters HA, Schmitt M, Brunner N, Harbeck N et al: Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease. Cancer Res 64: 4563-4568, 2004. (Pubitemid 38856929)
61. Rasch MG, Lund IK, Almasi CE and Hoyer-Hansen G: Intact and cleaved uPAR forms: diagnostic and prognostic value in cancer. Front Biosci 13: 6752-6762, 2008.
62. Sorio C, Mafficini A, Furlan F, Barbi S, Bonora A, Brocco G et al: Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group. BMC Cancer 11: 448, 2011.
63. Selleri C, Montuori N, Ricci P, Visconte V, Baiano A, Carriero MV et al: In vivo activity of the cleaved form of soluble urokinase receptor: a new hematopoietic stem/progenitor cell mobilizer. Cancer Res 66: 10885-10890, 2006. (Pubitemid 44876986)
64. Carlsson G, Ekelund L, Stigsson L and Hafstrom L: Vascularization and tumour volume estimations of solitary liver tumours in rats. Ann Chir Gynaecol 72: 187-191, 1983.